Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasmsBrady L Stein, Jason Gotlib, Murat Arcasoy, et al.
Nature Medicine|December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trialJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
Acta Haematologica|March 5, 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia VeraJohn Mascarenhas, Prithviraj Bose, Christopher Hillis, et al.
Nature Communications|January 17, 2025
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemiaTim Kong, Angelo B A Laranjeira, Christopher T Letson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid LeukemiaKim-Hien T Dao, Jason Gotlib, Michael M N Deininger, et al.
Blood Advances|November 24, 2020
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosisAaron T Gerds, Michael R Savona, Bart L Scott, et al.
JCO Precision Oncology|May 26, 2021
Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid LeukemiaErica K Barnell, Kenneth F Newcomer, Zachary L Skidmore, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Leukemia|October 4, 2024
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment responseMeagan A Jacoby, Eric D Duncavage, Ajay Khanna, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
Pageof 10